Prothena Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Prothena de 32.2% y 44.2% respectivamente, mientras que el BPA crecerá en un 32.3% al año.

Información clave

32.2%

Tasa de crecimiento de los beneficios

32.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	21.3%
Tasa de crecimiento de los ingresos	44.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	10 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23

Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Feb 08

Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Dec 20

Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Nov 24

Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Oct 27

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Aug 25

What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

May 10

We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Apr 23

Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

Mar 01

Bearish: Analysts Just Cut Their Prothena Corporation plc (NASDAQ:PRTA) Revenue and EPS estimates

May 08

Are Prothena Corporation plc (NASDAQ:PRTA) Investors Paying Above The Intrinsic Value?

Jan 10

Prothena: A Biotech Company With A Promising Pipeline

Dec 01

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PRTA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	228	-151	-112	N/A	5
12/31/2025	118	-220	-17	65	10
12/31/2024	13	-262	-229	110	9
12/31/2023	91	-147	-137	-134	N/A
9/30/2023	141	-73	-89	-88	N/A
6/30/2023	58	-141	-130	-129	N/A
3/31/2023	55	-128	-119	-119	N/A
12/31/2022	54	-117	-109	-109	N/A
9/30/2022	5	-156	-127	-126	N/A
6/30/2022	143	-1	16	17	N/A
3/31/2022	202	67	88	89	N/A
12/31/2021	201	67	92	93	N/A
9/30/2021	200	69	96	96	N/A
6/30/2021	61	-70	-36	-36	N/A
3/31/2021	1	-124	-91	-91	N/A
12/31/2020	1	-111	-81	-80	N/A
9/30/2020	1	-102	-76	-76	N/A
6/30/2020	1	-91	-66	-65	N/A
3/31/2020	1	-80	-59	-59	N/A
12/31/2019	1	-78	-54	-53	N/A
9/30/2019	1	-79	-62	-60	N/A
6/30/2019	1	-84	-86	-84	N/A
3/31/2019	1	-128	-16	-14	N/A
12/31/2018	1	-156	-30	-28	N/A
9/30/2018	1	-181	-47	-47	N/A
6/30/2018	1	-209	-32	-31	N/A
3/31/2018	27	-167	-126	-125	N/A
12/31/2017	28	-153	-135	-131	N/A
9/30/2017	27	-154	N/A	-125	N/A
6/30/2017	28	-145	N/A	-138	N/A
3/31/2017	1	-168	N/A	-129	N/A
12/31/2016	1	-160	N/A	-116	N/A
9/30/2016	1	-135	N/A	-102	N/A
6/30/2016	1	-115	N/A	-89	N/A
3/31/2016	1	-93	N/A	-73	N/A
12/31/2015	2	-81	N/A	-59	N/A
9/30/2015	3	-70	N/A	-55	N/A
6/30/2015	4	-60	N/A	-51	N/A
3/31/2015	19	-40	N/A	-33	N/A
12/31/2014	51	-7	N/A	-1	N/A
9/30/2014	49	-5	N/A	2	N/A
6/30/2014	48	-2	N/A	4	N/A
3/31/2014	33	-14	N/A	-9	N/A
12/31/2013	1	-41	N/A	-32	N/A
9/30/2013	1	-42	N/A	-38	N/A
6/30/2013	2	-41	N/A	-35	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PRTA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PRTA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PRTA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (44.2% al año) de PRTA crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (44.2% al año) de PRTA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PRTA se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Prothena Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 26%

Consensus revenue estimates fall by 78%

Prothena Corporation plc Provides Earnings Guidance for the Year 2024

Consensus revenue estimates increase by 63%

Consensus revenue estimates increase by 238%

Consensus revenue estimates fall by 29%

Recent updates

Prothena Corporation plc, Annual General Meeting, May 14, 2024

Consensus revenue estimates increase by 26%

Prothena Appoints David Ford to Newly Created Chief People Officer

New major risk - Revenue and earnings growth

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Prothena Corporation plc has filed a Follow-on Equity Offering in the amount of $250 million.

Prothena Corporation plc Announces Board Changes

Consensus revenue estimates fall by 78%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Prothena Corporation plc Provides Earnings Guidance for the Year 2024

Prothena Corporation plc to Report Q4, 2023 Results on Feb 15, 2024

Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%

Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?

Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business

Consensus revenue estimates increase by 63%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Prothena Corporation plc to Report Q3, 2023 Results on Nov 02, 2023

Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk

Prothena Reportedly Prepares for Potential Sale

Chief Accounting Officer & Controller notifies of intention to sell stock

Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth

Chief Accounting Officer & Controller notifies of intention to sell stock

Consensus revenue estimates increase by 238%

Chief Regulatory Officer notifies of intention to sell stock

Prothena Corporation plc to Report Q2, 2023 Results on Aug 03, 2023

Chief Operating Officer notifies of intention to sell stock

Prothena Corporation plc Presents New Research in the Treatment of Alzheimer's Disease At Alzheimer's Association International Conference®? 2023

Prothena C Corporation plc Announces Phase VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV Al Amyloidosis Treated with Birtamimab

Chief Regulatory Officer exercised options and sold US$1.2m worth of stock

CFO & Chief Strategy Officer exercised options and sold US$4.5m worth of stock

Prothena Corporation plc Appoints Billy Dunn to its Board of Directors

Consensus revenue estimates fall by 29%

What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today

Price target increased by 7.6% to US$92.10

Independent Director notifies of intention to sell stock

Prothena Corporation plc Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth

Chief Accounting Officer & Controller notifies of intention to sell stock

Chief Accounting Officer & Controller notifies of intention to sell stock

Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CFO & Chief Strategy Officer notifies of intention to sell stock

Prothena Corporation plc to Report Q4, 2022 Results on Feb 23, 2023

Prothena Corporation plc Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005

CFO & Chief Strategy Officer notifies of intention to sell stock

Independent Chairman notifies of intention to sell stock

We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate

CFO & Chief Strategy Officer notifies of intention to sell stock

Prothena Corporation plc Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

Independent Chairman exercised options and sold US$874k worth of stock

Chief Accounting Officer & Controller exercised options and sold US$420k worth of stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall by 18%

Third quarter 2022 earnings released: US$0.97 loss per share (vs US$2.39 profit in 3Q 2021)

Prothena Corporation plc to Report Q3, 2022 Results on Nov 03, 2022

CFO & Chief Strategy Officer notifies of intention to sell stock

Independent Chairman exercised options and sold US$1.3m worth of stock

Prothena: Paying A Premium To Cover All The Alzheimer's Bases

Price target increased to US$73.63

Chief Medical Officer notifies of intention to sell stock

Prothena Corporation plc Appoints Helen S. Kim to its Board of Directors

CFO & Chief Strategy Officer notifies of intention to sell stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Prothena Corporation plc Provides Earnings Guidance for the Year 2022

Prothena GAAP EPS of -$0.88 misses by $0.31

Chief Medical Officer notifies of intention to sell stock